Evaluation of p16/Ki-67 dual-stain as triage test for high-risk HPV-positive women: A hospital-based cross-sectional study

Cancer Cytopathol. 2022 Dec;130(12):955-963. doi: 10.1002/cncy.22628. Epub 2022 Jul 19.

Abstract

Background: Most human papillomavirus (HPV)-positive women recover from infections and do not develop cervical intraepithelial neoplasia (CIN) and cervical cancer. Additional triage approaches are needed to reduce unnecessary colposcopy referrals. The aim of this study is to determine the high-risk HPV prevalence in a hospital-based population and to evaluate the performance of p16/Ki-67 dual-stain test for the triage of high-risk HPV-positive women to detect precursor lesions and cervical cancer compared with the ThinPrep cytologic test (TCT).

Methods: In a hospital-based population, 100,801 women were provided with a primary HPV DNA test and only women with high-risk HPV infections were triaged using TCT and p16/Ki-67 dual-stain test. CIN2 or worse (≥CIN2) or CIN3 or worse (≥CIN3) were defined as the clinical end points.

Results: The p16/Ki-67 dual-stain indicated a statistically significant higher sensitivity (82.8% vs. 66.7%%), specificity (51.6% vs. 44.4%), positive predictive value (33.2% vs. 25.8%), negative predictive value (91.2% vs. 82.1%), and accuracy (58.6% vs. 49.4%) compared with TCT examination within ≥CIN2 cases. Similar patterns were observed for the ≥CIN3 end point.

Conclusions: Our study demonstrated that p16/Ki-67 dual-stain test could achieve better performance compared with TCT examination for ≥CIN2 or ≥ CIN3 detection, representing a promising approach as a specific and efficient triage strategy for high-risk HPV-positive women.

Keywords: cervical cancer screening; high-risk HPV; p16/Ki67 dual-stain.

MeSH terms

  • Coloring Agents
  • Cross-Sectional Studies
  • Cyclin-Dependent Kinase Inhibitor p16
  • Early Detection of Cancer
  • Female
  • Hospitals
  • Humans
  • Ki-67 Antigen
  • Papillomavirus Infections*
  • Sensitivity and Specificity
  • Triage
  • Uterine Cervical Dysplasia* / pathology
  • Uterine Cervical Neoplasms*

Substances

  • Ki-67 Antigen
  • Cyclin-Dependent Kinase Inhibitor p16
  • Coloring Agents